CANTON, Mass. – Collegium Pharmaceutical, Inc. ’s (COLL) stock is down nearly 10 percent in aftermarket trading after the company announced the U.S. Food and Drug Administration will not complete a review of the company’s extended-release opioid pain medication drug Xtampza. Michael Heffernan, Collegium’s chairman and chief executive officer, said the company remains confident […]
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
With not one but two record-shattering product launches that transformed the treatment of hepatitis C, Gilead more than doubled its revenue in a single year, earning its place as Med Ad News’ Company of the Year.
Med Ad News spoke with Paul Carter, Gilead’s executive VP of commercial operations, regarding the success of Sovaldi and Harvoni as well as the company’s vision of the future of biopharmaceuticals.
Amgen has been an independent biotech leader for years with an established array of blockbuster products, and now the company’s next wave of promising medicines is making its mark.
To accelerate the former, AstraZeneca has been engaging in a lot of the latter, as the company makes deals with other pharma and biotech companies as well as PatientsLikeMe.
U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such […]
Between new approvals, new drug applications and research collaborations with other companies, most of the big news about Bristol-Myers Squibb in the past year has concerned the company’s newest immuno-oncologic drug.
A three-part transaction with Novartis is anticipated to transform the future shape of GlaxoSmithKline, making the company more balanced and providing better opportunity for broadly based sales growth.
J&J’s innovation strategy has created an industry-leading pipeline and a cycle of success that positions the company for continued growth.